Madrigal pharmaceuticals reports second-quarter 2024 financial results and provides corporate updates

Conshohocken, pa., aug. 07, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash)/metabolic dysfunction-associated steatohepatitis (mash), today reports second-quarter 2024 financial results and provides corporate updates.
MDGL Ratings Summary
MDGL Quant Ranking